ALIBABA-CLOUD
19.3.2020 05:26:06 CET | Business Wire | Press release
Alibaba Cloud, the data intelligence backbone of Alibaba Group, said today it has offered medical personnel around the world advanced cloud-based technology applications in the fight against the COVID-19 pandemic.
The artificial intelligence-enhanced innovations are based on learnings and insights garnered during the initial outbreak of the virus.
The series of cloud-native anti-coronavirus solutions stem from joint efforts of Alibaba Cloud’s solution experts, scientists and researchers from Alibaba DAMO Academy and the technical team at DingTalk, one of the platforms UNESCO has tabbed as facilitating distance learning during the coronavirus outbreak.
While DingTalk might be better-known for supporting more than 120 million students across China with their live-streamed online classes, the team has taken it up a notch to launch DingTalk’s International Medical Expert Communication Platform , hosted on Alibaba Cloud. It provides a means of free communication for medical workers all over the world to directly contact doctors from medical institutions such as the First Affiliated Hospital of Zhejiang University and others in China, who have been on the frontline of the COVID-19 battle.
Through video conferencing and real-time AI translation into 11 languages (Arabic, Bahasa, Chinese, English, French, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), Alibaba Cloud aims to build a virtual community, inviting Chinese doctors to share their experiences and answer questions from global peers.
From Alibaba DAMO Academy, a global research initiative by Alibaba, three proven solutions are being made available via free trial for medical professionals and research institutes worldwide. Alibaba Cloud will work with local partners to deploy relevant services and solutions in accordance with local laws and regulations.
Epidemic Prediction Solution models epidemic characteristics of COVID-19 in a particular region, providing estimates of size, peak time and duration of the epidemic, as well as the spreading trends under three conditions - optimistic, neutral, and pessimistic. Based on machine learning, the algorithm was already tested on 31 provincial data in China and averaged 98% accuracy. It can serve as a reference to policymakers and medical researchers on prevention and control measures, medical resource allocation and travel advisories.
CT Image Analytics Solution is a CT image analytics technology service that can significantly improve testing accuracy and detection efficiency for diagnosing COVID-19. With deep-learning algorithms trained by data in China, the trained model can predict the probability of different pneumonia types, including the variety associated with COVID-19. It also performs computations of the proportion of lesions and the affected volume ratio to the entire lungs, by using the lung segmentation method. The whole test takes about 3 to 4 seconds to run and 15 to 16 seconds of transmission time, making it nearly 60 times faster than human detection. More than 160 hospitals in China are currently using the solution.
Genome Sequencing for Coronavirus Diagnostic Solution , an AI algorithm from Alibaba DAMO Academy and running on Alibaba Cloud, is a virus genome sequencing solution for coronavirus analytics, including viral genetic data screening, evolutionary analysis, protein structure analysis, and diagnostic reporting. It can complete the diagnosis of new coronavirus within 14 hours, which is five times faster than other available sequencing solutions in China. It can screen more than 20 people simultaneously, making the averaged time for each sample just around half an hour, much shorter than the normal two hours with the PCR method. The solution helps disease control centers, hospitals and clinics, and laboratories to address challenges such as insufficient nucleic acid detection capacity, high false-negative rates of the PCR method, and possible virus mutations.
Supporting advanced innovations during emergencies like COVID-19 requires extremely scalable supercomputing power. For this, Alibaba Cloud offers Elastic High-Performance Computing (E-HPC) Solution for Life Sciences , a cloud-native high-performance computing cluster solution designed for researchers working on life sciences applications, especially for Computational-Driven-Drug-Design (CDDD) and AI-Driven-Drug-Design (AIDDD). The solution already supports 20 research groups in China. For example, the intelligent CT diagnostic system on COVID-19 pneumonia developed by Tsinghua University can complete diagnosing in 10 seconds, and the performance of gene assembly by Sun Yat-sen University is accelerated by 25% utilizing the solution. Alibaba Cloud has also partnered with Global Health Drug Discovery Institute (GHDDI) in Beijing to launch an AI-driven-drug-discovery platform based on E-HPC.
For those looking to learn more about key lessons and experience from doctors and other medical personnel at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), the Jack Ma Foundation and Alibaba Foundation have also shared a handbook from the medical personnel covering what they’ve learned every step of the way, from screening to diagnosis and treatment of patients who contracted COVID-19. Medical personnel can download the handbook at https://covid-19.alibabacloud.com/ .
For more information about the above solutions available for global medical communities and businesses, please visit: https://www.alibabacloud.com/campaign/supports-your-business-anytime
Notes to the editors
The information in this press release should not be interpreted as offering medical advice or diagnostics, which should be given exclusively by authorized medical professionals in relevant jurisdiction. All data referred to are those as of writing of this summary, and Alibaba Cloud explicitly disclaim any warranty for accuracy or performance.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com ), the data intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom